Allarity Therapeutics Inc


Prices are adjusted according to historical splits.

Allarity Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.40 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Allarity Therapeutics Inc had its IPO on 2021-12-21 under the ticker symbol ALLR.

The company operates in the Healthcare sector and Biotechnology industry. Allarity Therapeutics Inc has a staff strength of 13 employees.

Stock update

Shares of Allarity Therapeutics Inc opened at $0.09 at the start of the last trading session i.e. 2023-03-25.

The stocks traded within a range of $0.07 - $0.1, and closed at $0.08.

This is a -31.86% slip from the previous day's closing price.

A total volume of 19,782,200 shares were traded at the close of the day’s session.

In the last one week, shares of Allarity Therapeutics Inc have slipped by -33.62%.

Allarity Therapeutics Inc's Key Ratios

Allarity Therapeutics Inc has a market cap of $3.40 million, indicating a price to book ratio of 2.659 and a price to sales ratio of 0.

In the last 12-months Allarity Therapeutics Inc’s revenue was $-7127000 with a gross profit of $-36348000 and an EBITDA of $-29374000. The EBITDA ratio measures Allarity Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Allarity Therapeutics Inc’s operating margin was 0% while its return on assets stood at -88.33% with a return of equity of -259.33%.

In Q3, Allarity Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Allarity Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-3.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allarity Therapeutics Inc’s profitability.

Allarity Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0989. Its price to sales ratio in the trailing 12-months stood at 0.

Allarity Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$23.19 million
Total Liabilities
$11.19 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Allarity Therapeutics Inc ended 2023 with $23.19 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.19 million while shareholder equity stood at $8.20 million.

Allarity Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $11.19 million in other current liabilities, 929000.00 in common stock, $-74229000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.64 million and cash and short-term investments were $7.64 million. The company’s total short-term debt was $54,000 while long-term debt stood at $1.06 million.

Allarity Therapeutics Inc’s total current assets stands at $10.08 million while long-term investments were $0.00 and short-term investments were $0. Its net receivables were $1.43 million compared to accounts payable of $5.56 million and inventory worth $0.

In 2023, Allarity Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Allarity Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Allarity Therapeutics Inc stock is currently trading at $0.08 per share. It touched a 52-week high of $3.38 and a 52-week low of $3.38. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $0.19 and 200-day moving average was $0.76 The short ratio stood at 0.14 indicating a short percent outstanding of 0%.

Around 1071.1% of the company’s stock are held by insiders while 62% are held by institutions.

Frequently Asked Questions About Allarity Therapeutics Inc

The stock symbol (also called stock or share ticker) of Allarity Therapeutics Inc is ALLR

The IPO of Allarity Therapeutics Inc took place on 2021-12-21

Similar Industry Stocks (Biotechnology)

Last Price
ageas SA/NV (AGESY)
Galp Energa (GLPEY)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.


210 Broadway, Cambridge, MA, United States, 02139